Hepatocyte growth factor/activin A/follistatin system activation during hemodialysis with different low molecular weight heparins

Renal Failure

Volumn 31, Issue 9, 2009, Pages 791-797

  Rydzewska Rosołowska, Alicja ^a   Borawski, Jacek ^a   Myśliwiec, Michał ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Activin A; Follistatin; Hemodialysis; Hepatocyte growth factor; Low molecular weight heparin

Indexed keywords

ACTIVIN A; DALTEPARIN; ENOXAPARIN; FOLLISTATIN; NADROPARIN; SCATTER FACTOR;

AGED; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACTIVINS; AGED; CROSS-OVER STUDIES; DALTEPARIN; ENOXAPARIN; FEMALE; FOLLISTATIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HEPATOCYTE GROWTH FACTOR; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; NADROPARIN; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 71049157578     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/08860220903180608     Document Type: Article

References (32)

1. Boros P, Miller CM. Hepatocyte growth factor: A multifunctional cytokine. Lancet. Feb 4 1995;345(8945):293-295.
2. Zarnegar R, Michalopoulos GK. The many faces of hepatocyte growth factor: From hepatopoiesis to hematopoiesis. J Cell Biol. Jun 1995;129(5):1177-1180.
3. Matsumoto K, Mizuno S, Nakamura T. Hepatocyte growth factor in renal regeneration, renal disease and potential therapeutics. Curr Opin Nephrol Hypertens. Jul 2000;9(4):395-402.
4. Maeshima A, Zhang YQ, Furukawa M, Naruse T, Kojima I. Hepatocyte growth factor induces branching tubulogenesis in MDCK cells by modulating the activin-follistatin system. Kidney Int. Oct 2000;58(4):1511-1522.
5. Niimi S, Hyuga M, Kazama H, et al. Activins A, AB, and B inhibit hepatocyte growth factor synthesis by MRC-5 human lung fibroblasts. Biol Pharm Bull. Nov 2002;25(11):1405-1408.
6. Werner S, Alzheimer C. Roles of activin in tissue repair, fibrosis, and inflammatory disease. Cytokine Growth Factor Rev. Jun 2006;17(3):157-171.
7. Maeshima A, Nojima Y, Kojima I. The role of the activinfollistatin system in the developmental and regeneration processes of the kidney. Cytokine Growth Factor Rev. Dec 2001;12(4):289-298.
8. Fareed J, Bick R. Differentiation of low-molecular-weight heparins: Practical implications. Clin Appl Thromb Hemost. Oct 2004;10(4):299-300. (Pubitemid 39391289)
9. Borawski J, Naumnik B, Mysliwiec M. Activation of hepatocyte growth factor/activin A/follistatin system during hemodialysis: Role of heparin. Kidney Int. Dec 2003;64(6):2229-2237.
10. Rampino T, Libetta C, De Simone W, et al. Hemodialysis stimulates hepatocyte growth factor release. Kidney Int. May 1998;53(5):1382-1388. (Pubitemid 28316902)
11. Sugimura K, Kim T, Goto T, et al. Serum hepatocyte growth factor levels in patients with chronic renal failure. Nephron. 1995;70(3):324-328.
12. Christidou F, Bamichas G, Galaktidou G, et al. Elevated hepatocyte growth factor levels at the beginning of high-flux hemodialysis are due to heparin administration. Ren Fail. 2008;30(9):861-864.
13. Borawski J, Mysliwiec M. Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in hemodialysis patients. Nephrol Dial Transplant. Apr 2002;17(4):637-644.
14. Jones KL, De Kretser DM, Phillips DJ. Effect of heparin administration to sheep on the release profiles of circulating activin A and follistatin. J Endocrinol. May 2004;181(2): 307-314.
15. Seidel C, Hjorth-Hansen H, Bendz B, et al. Hepatocyte growth factor in serum after injection of unfractionated and low molecular weight heparin in healthy individuals. Br J Haematol. Jun 1999;105(3):641-647.
16. Fareed J, Haas S, Sasahar A. Past, present and future considerations on low molecular weight heparin differentiation: An epilogue. Semin Thromb Hemost. 1999;25 (Suppl. 3):145-147.
17. Kakkar VV, Hoppenstead DA, Fareed J, et al. Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis. Blood. Mar 15 2002;99(6):1965-1970.
18. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. Apr 1 2005;23(10):2130-2135.
19. Borawski J, Naumnik B, Mysliwiec M. Plasma activin A in hemodialysis patients: Does brand of immunoassay matter? Kidney Int. Jul 2004;66(1):465.
20. Harada K, Shintani Y, Sakamoto Y, Wakatsuki M, Shitsukawa K, Saito S. Serum immunoreactive activin A levels in normal subjects and patients with various diseases. J Clin Endocrinol Metab. Jun 1996;81(6):2125-2130. (Pubitemid 26176707)
21. Matsumori A, Ono K, Okada M, Miyamoto T, Sato Y, Sasayama S. Immediate increase in circulating hepatocyte growth factor/scatter factor by heparin. J Mol Cell Cardiol. Oct 1998;30(10):2145-2149. (Pubitemid 28495339)
22. Zioncheck TF, Richardson L, DeGuzman GG, Modi NB, Hansen SE, Godowski PJ. The pharmacokinetics, tissue localization, and metabolic processing of recombinant human hepatocyte growth factor after intravenous administration in rats. Endocrinology. Apr 1994;134(4):1879-1887. (Pubitemid 24110751)
23. Liu KX, Kato Y, Kato M, Kaku TI, Nakamura T, Sugiyama Y. Existence of two nonlinear elimination mechanisms for hepatocyte growth factor in rats. Am J Physiol. Nov 1997;273(5 Pt 1):E891-E897.
24. Matsumoto K, Tajima H, Okazaki H, Nakamura T. Heparin as an inducer of hepatocyte growth factor. J Biochem (Tokyo). Dec 1993;114(6):820-826.
25. Yasuda S, Noguchi T, Gohda M, et al. Single low-dose administration of human recombinant hepatocyte growth factor attenuates intimal hyperplasia in a balloon-injured rabbit iliac artery model. Circulation. May 30 2000;101(21):2546-2549.
26. Rampino T, Arbustini E, Gregorini M, et al. Hemodialysis prevents liver disease caused by hepatitis C virus: Role of hepatocyte growth factor. Kidney Int. Dec 1999; 56(6):2286-2291.
27. Chen XH, Minatoguchi S, Kosai K, et al. In vivo hepatocyte growth factor gene transfer reduces myocardial ischemiareperfusion injury through its multiple actions. J Card Fail. Dec 2007;13(10):874-883.
28. Shimamura M, Sato N, Waguri S, et al. Gene transfer of hepatocyte growth factor gene improves learning and memory in the chronic stage of cerebral infarction. Hypertension. Apr 2006;47(4):742-751.
29. Li H, Jiang T, Lin Y, Zhao Z, Zhang N. HGF protects rat mesangial cells from high-glucose-mediated oxidative stress. Am J Nephrol. 2006;26(5):519-530.
30. Kuroiwa T, Iwasaki T, Imado T, Sekiguchi M, Fujimoto J, Sano H. Hepatocyte growth factor prevents lupus nephritis in a murine lupus model of chronic graft-versus-host disease. Arthritis Res Ther. Jul 19 2006;8(4):R123.
31. Malatino LS, Cataliotti A, Benedetto FA, et al. Hepatocyte growth factor and left ventricular geometry in end-stage renal disease. Hypertension. Jan 2003;41(1):88-92.
32. Hammerstingl C. Monitoring therapeutic anticoagulation with low molecular weight heparins: Is it useful or misleading? Cardiovasc Hematol Agents Med Chem. Oct 2008;6(4):282-286.